SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gains on getting NoC for generic Mesalamine suppositories 1000 mg

27 Oct 2025 Evaluate

Zydus Lifesciences is currently trading at Rs. 1013.00, up by 7.35 points or 0.73% from its previous closing of Rs. 1005.65 on the BSE.

The scrip opened at Rs. 1006.05 and has touched a high and low of Rs. 1013.00 and Rs. 1003.50 respectively. So far 15609 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1014.95 and Rs. 985.65 respectively. The current market cap of the company is Rs. 101845.97 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.20% and 6.80% respectively.

Zydus Lifesciences has received Notice of Compliance (NoC) from Health Canada for generic Mesalamine suppositories 1000 mg. Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis.

ZDS - Mesalamine suppositories will be manufactured at Zydus Lifesciences Changodar, Ahmedabad in Gujarat, India. Mesalamine suppositories had annual sales of 4.86 million CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025). 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

923.10 7.65 (0.84%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×